Aclaris Therapeutics

ACRS · NASDAQ

$3.77+$0.29 (+8.33%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.48

About ACRS

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 69 full-time employees. The company went IPO on 2015-10-07. The firm is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. The company provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).

Employees: 69
Headquarters: Wayne, Pennsylvania
Listed: Oct 7, 2015
Sector: Health Care
Industry: Pharmaceuticals
Website: aclaristx.com

Leadership

Aclaris Therapeutics executives
Name	Title	Since	Age
Neal Walker	—	2012	55
Hugh Davis	—	2024	66
Kevin Balthaser	—	—	38
Roland Kolbeck	—	—	—
Jesse Hall	—	—	—
James Loerop	—	—	61
Christopher Molineaux	—	—	59
Maxine Gowen	—	—	67
William Humphries	—	—	58
Anand Mehra	—	—	49
Vincent Milano	—	—	61
Andrew Schiff	—	—	58

Revenue by product and region

Fiscal year ended Dec 31, 2025: $7.83M total revenue

By product

License and Service [Member]$5.95M76.1%
Laboratory service revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered. Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.$1.87M23.9%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Aclaris Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Novan NOVN	Customer	US	0.59
Washington University in St. Louis	Supplier and customer	US	—

Similar companies

Companies in the same industry as Aclaris Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.